The company has 8.9 months of cash left based on the quarterly cash burn of $1.07 M and estimated current cash of $3.16 M

Nutriband Inc. is facing significant financial challenges, having incurred a net loss of $10,482,617 for the year ended January 31, 2025, and used $4,626,564 in cash for operations. Despite these losses, the company has alleviated substantial doubt about its ability to continue as a going concern through an $8,400,000 equity financing and a $5,000,000 credit line facility. The company requires approximately $13 million for the development of its abuse deterrent fentanyl transdermal system, with potential costs exceeding this amount, indicating a need for further capital. Management believes that sufficient funds will be generated from operations to sustain the company for one year, but ongoing reliance on external financing remains critical., Filed At: 2025-04-28